Word

AFFIBODY

Status

Pending

Status Code

660

Status Date

Monday, September 16, 2024

Serial Number

79374502

Mark Type

3

Filing Date

Friday, March 31, 2023

Trademark Owner History

Affibody AB

Classifications

5 Medical and veterinary substances, preparations and articles, namely, Medical diagnostic reagents and assays, Clinical diagnostic reagents, Diagnostic biomarker reagents for medical purposes, Diagnostic reagents and agents for medical diagnostic use, Diagnostic reagents for clinical laboratory use, Reagents for use in medical genetic testing, Chemicals for use in chromatography (medical, surgical, dental and veterinary), Radiopharmaceutical imaging and detection agents for diagnosing and monitoring cancer; pharmaceutical preparations and substances, biochemical preparations, biological preparations, and antibodies and antibodies-based pharmaceutical preparations for the treatment of neoplasms, cancer diseases, inflammatory eye, skin, muscle and joint diseases and disorders, diseases and disorders of the immune system, autoimmune diseases and disorders, local and systemic bacterial infections, viral infections, fungal infections, central nervous system [CNS] diseases, circulatory system, respiratory system, respiratory diseases and disorders, cardiovascular diseases, renal diseases, liver diseases, skin diseases, diseases of the digestive system, gastro-intestinal diseases, eye diseases and conditions, diseases of the musculoskeletal system or connective tissue; pharmaceutical preparations and substances, biochemical preparations, biological preparations, and antibodies and antibodies-based pharmaceutical preparations for the treatment of diseases and disorders of the peripheral nervous system, namely cranial and spinal neuropathies, autonomic neuropathies, sensorimotor neuropathies and plexopathies, diseases of the blood or blood forming organs; pharmaceutical preparations, biochemical preparations, biological preparations, and antibodies and antibodies-based pharmaceutical preparations for the treatment of disorders of the lymphatic systems namely Lymphangitis, Lymphocytosis, and Mesenteric lymphadenitis; pharmaceutical preparations, biochemical preparations, biological preparations, and antibodies and antibodies-based pharmaceutical preparations for the treatment of metabolic diseases namely obesity, diabetes, metabolic syndrome, inborn errors of metabolism, hypoglycaemia, gout, osteoarthritis, muscular dystrophy, anemia; pharmaceutical preparations, biochemical preparations, biological preparations, and antibodies and antibodies-based pharmaceutical preparations for the treatment of diseases of the endocrine system, namely glucose homeostasis disorders, thyroid disorders, calcium homeostasis disorders and metabolic bone disease, pituitary gland disorders, sex hormone disorders and tumours of the endocrine glands; pharmaceutical preparations, biochemical preparations, biological preparations, and antibodies and antibodies-based pharmaceutical preparations for use in ophthalmology; pharmaceutical preparations, biochemical preparations, biological preparations, and antibodies and antibodies-based pharmaceutical preparations for the treatment of diseases of the genitourinary system, namely prostate, reproductive and urological diseases and disorders; diagnostic preparations and materials for medical purposes; medical therapeutic agents for regulation of biological functions, protein inhibition or activation, weight control and appetite suppression; reagents for medical, surgical, veterinary and dental use; biochemical biomarkers for medical use; diagnostic biomarker reagents for medical purposes; sanitary preparations for medical purposes

1 Chemical substances and materials for industrial, scientific and laboratory use other than for medical or veterinary purposes; chemical reagents other than for medical or veterinary purposes, biochemical preparations for scientific purposes; biochemical substances for scientific purposes; chemical substances for use in the production of drugs, pharmaceuticals and antibodies; reagents for scientific, laboratory, analysis, research, medical research, testing, inspection, detecting or verification use other than for medical or veterinary purposes; reagents for use in the development of antibodies other than for medical or veterinary purposes; reagents for use in scientific apparatus for chemical or biological analysis other than for medical or veterinary purposes; antibodies and antibodies-based chemicals, except for medical or veterinary use

44 Human healthcare services; medical services; providing medical information; physical examination; medical diagnostic testing, monitoring and reporting services; optical medical imaging for medical diagnostic use; medical analysis services for diagnostic and treatment purposes provided by medical laboratories; medical testing for diagnostic or treatment purposes

10 Medical and veterinary apparatus and instruments, namely, medical apparatus and instruments for use in surgery, chromatography media for use in medical research; diagnostic, examination, and monitoring equipment namely, medical apparatus and instruments for diagnostic radiopharmaceutical use, contrast media for use in diagnosis and monitoring of disease; screening apparatus and instruments for medical purposes, namely, ultrasonic medical diagnostic apparatus; ELISA kits for medical assay purposes, containing pre-coated plates, detection reagents, buffers, diluents, standards, and substrates, capture reagent on surface plasmon resonance (SPR) sensor chip, capture reagent on microarrays; separation instruments for medical use, namely, tubing and valve assembly set and electromechanical fluidic instrument, and other similar or related devices, which process human whole blood for the purpose of separating human blood components for use in blood transfusions and washing human red blood cells with clinical medical reagents for use in blood transfusions chromatography columns for use in affinity separation, chromatography media for use in affinity separation; gas chromatographic instruments for medical use; diagnostic imaging apparatus for medical use; medication fluid injectors

42 Scientific research, technological research, product development and design in the field of biotechnics and diagnostics; medical and pharmacological research services for medical purposes in the field of biotechnics and diagnostics; medical, pharmaceutical and biotechnological laboratory research services for medical purposes in the field of biotechnics and diagnostics; scientific investigations for medical purposes; medical and scientific research, namely, conducting clinical trials for others; providing scientific information about the results of clinical trials for pharmaceutical products; scientific advisory services relating to diagnostic preparations; biochemical analysis and research for medical purposes in the field of biotechnics and diagnostics; drug discovery services; pharmaceutical products development and evaluation

The mark consists of the black wording, "AFFIBODY" at right; the blue design of three solid circles over a solid, curved band appears at left; the color white represents background, outlining, shading and/or transparent areas and is not part of the mark.
The color(s) black and blue is/are claimed as a feature of the mark.

Trademark Events

Dec 29, 2023

Non-Final Action (Ib Refusal) Prepared For Review

Jan 11, 2024

Non-Final Action Mailed - Refusal Sent To Ib

Jan 11, 2024

Refusal Processed By Mpu

Jan 31, 2024

Refusal Processed By Ib

Jul 20, 2023

Sn Assigned For Sect 66a Appl From Ib

Jul 21, 2023

New Application Office Supplied Data Entered

Jul 25, 2023

Application Filing Receipt Mailed

Dec 27, 2023

Assigned To Examiner

Dec 28, 2023

Non-Final Action Written

Jul 9, 2024

Teas/Email Correspondence Entered

Jul 9, 2024

Correspondence Received In Law Office

Jul 9, 2024

Teas Response To Office Action Received

Sep 11, 2024

Final Refusal E-Mailed

Sep 11, 2024

Final Refusal Written

Sep 11, 2024

Notification Of Final Refusal Emailed

Sep 16, 2024

Subsequent Final Emailed

Sep 16, 2024

Subsequent Final Refusal Written

Sep 16, 2024

Notification Of Subsequent Final Emailed